[HTML][HTML] Effectiveness, tolerability and prescribing choice of antiviral molecules molnupiravir, remdesivir and nirmatrelvir/r: a real-world comparison in the first ten …
C Del Borgo, S Garattini, C Bortignon, A Carraro… - Viruses, 2023 - mdpi.com
In 2022, three antiviral drugs—molnupiravir, remdesivir and nirmatrelvir/ritonavir—were
introduced for treatment of mild-to-moderate COVID-19 in high-risk patients. The aim of this …
introduced for treatment of mild-to-moderate COVID-19 in high-risk patients. The aim of this …
[HTML][HTML] Efficacy and safety of nirmatrelvir/ritonavir, molnupiravir, and remdesivir in a real-world cohort of outpatients with COVID-19 at high risk of progression: the …
G Tiseo, C Barbieri, V Galfo, S Occhineri… - Infectious Diseases and …, 2023 - Springer
Introduction Different antivirals are available for the treatment of outpatients with COVID-19.
Our aim was to describe a real-world experience of outpatient management of COVID-19 …
Our aim was to describe a real-world experience of outpatient management of COVID-19 …
[HTML][HTML] The clinical efficacy and safety of anti-viral agents for non-hospitalized patients with COVID-19: a systematic review and network meta-analysis of randomized …
CC Lai, YH Wang, KH Chen, CH Chen, CY Wang - Viruses, 2022 - mdpi.com
This network meta-analysis compared the clinical efficacy and safety of anti-viral agents for
the prevention of disease progression among non-hospitalized patients with COVID-19 …
the prevention of disease progression among non-hospitalized patients with COVID-19 …
[HTML][HTML] Antiviral drugs against SARS-CoV-2
The use of antiviral drugs represents an important progress in the therapeutic management
of COVID-19, leading to a substantial reduction of SARS-CoV-2-related complications and …
of COVID-19, leading to a substantial reduction of SARS-CoV-2-related complications and …
[HTML][HTML] Current status of oral antiviral drug treatments for SARS-CoV-2 infection in non-hospitalized patients
DV Parums - … science monitor: international medical journal of …, 2022 - ncbi.nlm.nih.gov
On 4 th November 2021, the first oral antiviral drug for COVID-19, molnupiravir (Lagevrio®),
received full regulatory approval from the Medicines and Healthcare Products Regulatory …
received full regulatory approval from the Medicines and Healthcare Products Regulatory …
Effectiveness of remdesivir, lopinavir/ritonavir, and favipiravir for COVID-19 treatment: a systematic review
WF Qomara, DN Primanissa, SH Amalia… - … journal of general …, 2021 - Taylor & Francis
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel
strain that causes acute respiratory illnesses known as coronavirus disease 2019 (COVID …
strain that causes acute respiratory illnesses known as coronavirus disease 2019 (COVID …
[HTML][HTML] Effectiveness of oral nirmatrelvir/ritonavir vs. intravenous three-day remdesivir in preventing progression to severe COVID-19: a single-center, prospective …
Background: Nirmatrelvir/ritonavir (NMV/r) and three-day course remdesivir (3RDV) have
been approved as early treatments for COVID-19 outpatients not requiring supplemental …
been approved as early treatments for COVID-19 outpatients not requiring supplemental …
Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis
M Zur, T Peselev, S Yanko, V Rotshild, I Matok - Antiviral Research, 2023 - Elsevier
Background Remdesivir, molnupiravir, and nirmatrelvir/ritonavir are three antiviral agents
approved by FDA emergency authorization for treating mild to moderate symptomatic COVID …
approved by FDA emergency authorization for treating mild to moderate symptomatic COVID …
[HTML][HTML] Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2 …
WHK Schilling, P Jittamala, JA Watson… - The Lancet Infectious …, 2024 - thelancet.com
Background Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-
19 antiviral treatments, but their antiviral activities in patients have not been compared …
19 antiviral treatments, but their antiviral activities in patients have not been compared …
[HTML][HTML] Nirmatrelvir/ritonavir and molnupiravir in the treatment of mild/moderate COVID-19: results of a real-life study
I Gentile, R Scotto, N Schiano Moriello, B Pinchera… - Vaccines, 2022 - mdpi.com
Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …